{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+With+Oligodendroglial+Component",
    "query": {
      "condition": "Glioblastoma With Oligodendroglial Component"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T01:44:42.527Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01480479",
      "title": "Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma",
        "Small Cell Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma",
        "Glioblastoma With Oligodendroglial Component"
      ],
      "interventions": [
        {
          "name": "Rindopepimut (CDX-110) with GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "KLH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 745,
      "start_date": "2011-11",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-05-22T01:44:42.527Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01480479"
    },
    {
      "nct_id": "NCT01498328",
      "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Small Cell Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma",
        "Glioblastoma With Oligodendroglial Component",
        "Recurrent Glioblastoma",
        "Relapsed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Rindopepimut (CDX-110) with GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "KLH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-12",
      "completion_date": "2016-05-17",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-05-22T01:44:42.527Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498328"
    },
    {
      "nct_id": "NCT00960492",
      "title": "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "XL184",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-09",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-05-22T01:44:42.527Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960492"
    },
    {
      "nct_id": "NCT03746080",
      "title": "Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma With Primitive Neuronal Component",
        "Gliosarcoma",
        "Malignant Glioma",
        "Oligodendroglial Component Present"
      ],
      "interventions": [
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Whole-Brain Radiotherapy (WBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Lawrence D Recht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-12-04",
      "completion_date": "2024-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-05-22T01:44:42.527Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03746080"
    }
  ]
}